Top ▲
Target not currently curated in GtoImmuPdb
Target id: 1932
Nomenclature: ankyrin repeat and kinase domain containing 1
Abbreviated Name: SgK288
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 765 | 11q23.2 | ANKK1 | ankyrin repeat and kinase domain containing 1 | |
Mouse | - | 745 | 9 A5.3 | Ankk1 | ankyrin repeat and kinase domain containing 1 | |
Rat | - | - | 8 q23 | Ankk1 | ankyrin repeat and kinase domain containing 1 |
Previous and Unofficial Names |
X-kinase | Protein kinase PKK2 | Sugen kinase 288 |
Database Links | |
Alphafold | Q8NFD2 (Hs), Q8BZ25 (Mm) |
BRENDA | 2.7.11.1 |
CATH/Gene3D | 1.25.40.20 |
ChEMBL Target | CHEMBL5547 (Hs) |
Ensembl Gene | ENSG00000170209 (Hs), ENSMUSG00000032257 (Mm), ENSRNOG00000025037 (Rn) |
Entrez Gene | 255239 (Hs), 244859 (Mm), 367080 (Rn) |
Human Protein Atlas | ENSG00000170209 (Hs) |
KEGG Enzyme | 2.7.11.1 |
KEGG Gene | hsa:255239 (Hs), mmu:244859 (Mm), rno:367080 (Rn) |
OMIM | 608774 (Hs) |
Pharos | Q8NFD2 (Hs) |
RefSeq Nucleotide | NM_178510 (Hs), NM_172922 (Mm) |
RefSeq Protein | NP_848605 (Hs), NP_766510 (Mm) |
UniProtKB | Q8NFD2 (Hs), Q8BZ25 (Mm) |
Wikipedia | ANKK1 (Hs) |
Enzyme Reaction | ||||
|
DiscoveRx KINOMEscan® screen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 1-2 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: ANKK1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
1. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
2. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]
Receptor interacting protein kinase (RIPK) family: ankyrin repeat and kinase domain containing 1. Last modified on 25/04/2017. Accessed on 10/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1932.